Novo Nordisk STEPs Into Heart Failure
More Success For Obesity And Diabetes Blockbuster Semaglutide
Executive Summary
The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.
You may also be interested in...
Corteria Rides Wave Of Renewed Interest In Heart Failure
A French biotech led by Philip Janiak, former head of cardiovascular research at Sanofi, is looking to bring therapies to heart failure subpopulations with high unmet needs.
Now Europe’s Most Valuable Company, Can Novo Nordisk Live Up To Investor Expectations?
Novo Nordisk has just become Europe’s most valuable company based on Wegovy’s huge success so far and future potential - but just how big could the obesity market get?
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things podcast: US Medicare price negotiations get soft landing; Medicare negotiations and patent cliff acceleration; Novo Nordisk steps into heart failure; PCSK9s and the convenience battle; and an investor’s view of Korean biotech potential.